Neurotech CCO Scott Hunter passes away

(Image credit: Neurotech Pharmaceuticals Inc.)

Scott Hunter, Chief Commercial Officer of Neurotech Pharmaceuticals Inc., passed away on December 3, 2024.

Hunter joined Neurotech in January 2023.

“The entire Neurotech family mourns this loss,” the company said in a statement. “On behalf of the Board of Directors, the management team, and employees, we extend our deepest sympathies to Scott’s family.”

In the statement, Neurotech noted that Hunter brought his passion, experience, and energy to the company.

“He was an exceptional partner and instrumental in building the commercial strategy and infrastructure,” the company added in its news release. “Scott loved his family, friends, and sports, and spent more than two decades in eyecare working in rare disease and specialty markets. He will be deeply missed.”

Prior to joining Neurotech, Hunter worked at Novartis, where he was the Global Marketing Head for Luxturna (voretigene neparvovec-rzyl), responsible for advancing the global strategy for the first commercially approved ocular gene therapy.

Before Novartis, Hunter was at Shire, where he was instrumental in building the US ophthalmics franchise and launching Xiidra, culminating in the divestiture to Novartis for up to $5.3 billion.

Hunter also spent 12 years at Bausch + Lomb, where he held roles of increasing responsibility across research and development and marketing. He earned his master’s degree in Pharmacoeconomics from the University of Florida and his MBA from the University of Tampa after completing his bachelor’s degree in Biology at the University of South Florida.

Funeral arrangements are pending.